Aldeyra Therapeutics FY Conference Summary Company Overview - **Company**: Aldeyra Therapeutics (NasdaqCM: ALDX) - **Focus**: Development of pharmaceuticals targeting immune-mediated diseases through RASP modulators - **Key Products**: - Reproxalap: Treatment for dry eye disease and allergic conjunctivitis - ADX-2191: Novel formulation for primary vitreoretinal lymphoma and retinitis pigmentosa - ADX-248 and ADX-246: Oral treatments for atopic dermatitis and other conditions Key Points and Arguments Regulatory Updates - **PDUFA Date**: Extended to March 16, 2026, for reproxalap's approval for dry eye disease [2][4] - **Regulatory History**: - Received a Complete Response Letter (CRL) in 2023 due to a missed co-primary endpoint [4] - A second CRL was issued for a baseline imbalance, which is considered unique [5] - Resubmitted NDA with additional trial data, leading to the current PDUFA extension [6][7] Market Positioning - **Reproxalap's Differentiation**: - Potential to be the only drug with a rapid onset of action (minutes) for dry eye treatment [10][11] - Unique ability to control redness, which is significant for patient satisfaction [12] - **Allergic Conjunctivitis**: - Completed two positive Phase 3 trials, with plans for a supplemental NDA following dry eye approval [13][14] Partnership with AbbVie - **Terms of Agreement**: - AbbVie has an option to market reproxalap, with a $200 million potential payout upon approval [19][20] - Revenue split post-approval: 60% to AbbVie, 40% to Aldeyra [20] - **Collaboration**: Ongoing partnership for both dry eye and allergic conjunctivitis indications [18] Pipeline and Future Developments - **Upcoming Milestones**: - Focus on allergic conjunctivitis following dry eye approval [21] - Plans for NDA submission for ocular lymphoma (primary vitreoretinal lymphoma) [22] - **ADX-248 for Atopic Dermatitis**: - Positioned as a more potent oral treatment, currently in Phase 1 trials [26][27] Financial Outlook - **Cash Position**: - Reported $75 million in cash as of Q3, providing approximately two years of runway [28] - Budget allocation includes reserves for potential dry eye trials and support for ongoing programs [28][29] Additional Insights - **Market Landscape**: The dry eye treatment market is expanding, with various new agents being introduced, but none offering the rapid relief that reproxalap promises [9][10] - **Patient Considerations**: Emphasis on the importance of both efficacy and cosmetic outcomes for patients suffering from dry eye and allergic conjunctivitis [11][12] This summary encapsulates the critical aspects of Aldeyra Therapeutics' recent conference, highlighting the company's strategic positioning, regulatory challenges, and future opportunities in the biotechnology sector.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. ...

AbbVie (NYSE: ABBV) is a large drug company with a somewhat unusual portfolio of products, spanning immunology (Skyrizi and Rinvoq) to esthetics (Botox). However, for many investors, the big draw is going to be the dividend. With a currently high yield and strong cash flow, AbbVie could provide dividend lovers with reliable income for years to come. AbbVie's yield is attractive The S&P 500 index has a paltry yield of 1.1% today. The average pharmaceutical company, using iShares U.S. Pharmaceuticals ETF a ...

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference [Accessibility Statement] Skip NavigationNORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at [investors.abbvie.com]. An archived edition of the sess ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Dive Brief: AbbVie announced it will spend $380 million to build two new U.S. facilities at its existing campus in North Chicago, Illinois that will integrate advanced manufacturing technologies with artificial intelligence to produce next-generation neuroscience and obesity drugs. Construction will begin in spring of 2026, with the plants scheduled ...

Investment Plans - AbbVie has announced a $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities in North Chicago, Illinois, integrating advanced manufacturing technologies and AI for obesity and next-generation neuroscience medications [1][2] - Construction is set to begin in spring 2026, with both facilities expected to be operational by 2029 [1] Employment and Capacity Expansion - The company plans to hire 300 employees in North Chicago, including manufacturing operators, scientists, lab technicians, and engineers to support the expanded operations [2] - AbbVie has been increasing its API manufacturing capacity in the US over the past six months [2] Relocation of Production - In September 2025, AbbVie initiated the first phase of this investment by breaking ground on a chemical synthesis facility aimed at relocating API production for certain neuroscience, immunology, and oncology products from Europe and Asia back to the US [3] Additional Investments - AbbVie has also revealed plans for a device manufacturing facility acquisition in Arizona and significant investments at its Massachusetts site, with further investments in other US states expected to be announced in 2026 [4] - The chairman and CEO stated that this milestone reflects progress towards a $100 billion commitment to US R&D and capital investments over the next decade [4] Strategic Acquisitions - In August 2025, AbbVie signed an agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.2 billion, which includes upfront payments and development milestones [5]

AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL. This establishes the first and only all-oral, fixed-duration regimen for previously untreated patients, providing a new alternative to traditional chemoimmunotherapy. By combining two classes of oral medications, the treatment offers patients the potential for periods ...

格隆汇2月24日｜艾伯维表示，将投资3.8亿美元在美国伊利诺伊州园区建造两座新的活性药物成分生产 设施，以扩大其神经科学和减肥药物的国内生产能力。 公司在美国已经拥有11个生产基地，并且正在 与美国多个州就潜在项目进行磋商，预计将于今年宣布进一步投资。 ...

AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential On February 20, Barclays began coverage of AbbVie Inc. (NYSE:ABBV) with an Overweight rating. It set a price target of $275 on the stock. The firm said current consensus estimates do not fully reflect AbbVie’s operating leverage potential. In its note, Barclays added that positive results from any of the company’s proof-of-concept s ...

AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its... ...